{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:59:56Z","timestamp":1793789996263,"version":"4.6.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FOREUM Foundation for Research"},{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Service"},{"DOI":"10.13039\/501100000276","name":"UK Department of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To describe the baseline characteristics, biologic DMARD (bDMARD) response and drug survival of axial SpA (axSpA) patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The BSRBR-AS is a national prospective cohort including axSpA participants classified according to the Assessment of SpondyloArthritis international Society criteria. In this analysis, baseline data of patients starting bDMARDs were compared. Ankylosing Spondylitis Disease Activity Scores (ASDASs) for low disease status, clinically important improvement (CII) and major improvement (MI) at 1\u2009year were used to assess treatment response. Cox proportional hazards analysis was performed after adjusting for clinically relevant confounders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1145 axSpA patients were included. Higher male prevalence, older age and longer disease duration were seen in the radiographic axSpA (r-axSpA) subgroup. Based on a complete case analysis (290 patients), two-thirds of patients achieved an ASDAS low disease state at 1\u2009year regardless of radiographic status [non-radiographic axSpA (nr-axSpA) 64.2% vs r-axSpA 66.1]. No statistically significant differences were seen between the subgroups in attaining ASDAS CII (nr-axSpA 50.7% vs r-axSpA 44.7%) or MI (nr-axSpA 20% vs r-axSpA 18.7%). Drug survival probability curves were similar for both subgroups and the hazard ratio for nr-axSpA\/axSpA was 0.94 (95% CI 0.69, 1.28) when adjusted for sex, age, baseline ASDAS with CRP, smoking status, disease duration, HLA-B27 and prescribed biologic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although there appeared to be some differences in the baseline characteristics when exploring this cohort according to radiographic status, which are likely related to the natural history of the disease, the level of biologic response and drug survival was comparable between nr-axSpA and r-axSpA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab070","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T12:17:31Z","timestamp":1611058651000},"page":"5795-5800","source":"Crossref","is-referenced-by-count":18,"title":["Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-919X","authenticated-orcid":false,"given":"Xabier","family":"Michelena","sequence":"first","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng Steven","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9303-7122","authenticated-orcid":false,"given":"Sayam","family":"Dubash","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7667-5352","authenticated-orcid":false,"given":"Linda E","family":"Dean","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-7591","authenticated-orcid":false,"given":"Gareth T","family":"Jones","sequence":"additional","affiliation":[{"name":"Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"2021121823174681900_keab070-B1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"2021121823174681900_keab070-B2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021121823174681900_keab070-B3","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"key":"2021121823174681900_keab070-B4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41584-019-0331-6","article-title":"Axial spondyloarthritis: time to stop the split 10 years on","volume":"16","author":"Michelena","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2021121823174681900_keab070-B5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021121823174681900_keab070-B6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","article-title":"Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021121823174681900_keab070-B7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","article-title":"ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis","volume":"55","author":"van der Heijde","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2021121823174681900_keab070-B8","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021121823174681900_keab070-B9","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/rheumatology\/kew230","article-title":"Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics","volume":"55","author":"Sieper","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2021121823174681900_keab070-B10","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3899\/jrheum.150372","article-title":"Tumor necrosis factor-\u03b1 inhibition in ankylosing spondylitis and nonradiographic axial spondyloarthritis: treatment response, drug survival, and patient outcome","volume":"42","author":"Corli","year":"2015","journal-title":"J Rheumatol"},{"key":"2021121823174681900_keab070-B11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s13075-015-0897-6","article-title":"Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients\u2014baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice","volume":"17","author":"Wallman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2021121823174681900_keab070-B12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.160958","article-title":"Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 status. An observational cohort study from the nationwide DANBIO registry","volume":"44","author":"Glintborg","year":"2017","journal-title":"J Rheumatol"},{"key":"2021121823174681900_keab070-B13","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021121823174681900_keab070-B14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12891-015-0805-x","article-title":"The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment","volume":"16","author":"Macfarlane","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"2021121823174681900_keab070-B15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.38921","article-title":"Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity C-reactive protein is used: an analysis in the DESIR cohort","volume":"67","author":"Machado","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021121823174681900_keab070-B16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/1744666X.2018.1477591","article-title":"Radiographic progression in non-radiographic axial spondyloarthritis","volume":"14","author":"Protopopov","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2021121823174681900_keab070-B17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3899\/jrheum.180538","article-title":"Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study","volume":"46","author":"Derakhshan","year":"2019","journal-title":"J Rheumatol"},{"key":"2021121823174681900_keab070-B18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/annrheumdis-2012-202976","article-title":"Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme","volume":"73","author":"Fern\u00e1ndez-Espartero","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021121823174681900_keab070-B19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","article-title":"Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE","volume":"7","author":"Landewe","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2021121823174681900_keab070-B20","first-page":"762","article-title":"Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey","volume":"37","author":"Lopalco","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2021121823174681900_keab070-B21","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","article-title":"Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS","volume":"59","author":"Macfarlane","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2021121823174681900_keab070-B22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3899\/jrheum.160079","article-title":"Limited reliability of radiographic assessment of sacroiliac joints in patients with suspected early spondyloarthritis","volume":"44","author":"Christiansen","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab070\/36417801\/keab070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/12\/5795\/41820340\/keab070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/12\/5795\/41820340\/keab070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:24:48Z","timestamp":1639869888000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/12\/5795\/6121329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab070","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,1,27]]}}}